prostate cancer | Research | Treatment | 10 pages | source: European urology focus | Added Oct 10, 2021
Apalutamide plus androgen deprivation therapy preserves health-related quality of life in patients with non-metastatic castration-resistant prostate cancer.
This study reported the long-term effects on the health-related quality of life (HR-QoL) of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that apalutamide plus ADT preserved HR-QoL in these patients.
prostate cancer | Research | Treatment | 8 pages | source: Cancer | Added Sep 25, 2021
Evaluating bone density testing in prostate cancer patients treated with hormone therapy
The study assessed the frequency of bone density testing among prostate cancer patients treated with androgen-deprivation therapy.
prostate cancer | Research | 12 pages | source: Urology | Added Sep 23, 2021
How often does the urethra become blocked following prostate cancer treatment?
The authors evaluated the prevalence and management of urethral blockage following certain cancer treatments.
prostate cancer | Research | 17 pages | source: Annals of internal medicine | Added Sep 13, 2021
How much do age, chronic illness, and tumor characteristics affect patient survival?
This study investigated the impact of age, comorbidities (the existence of other illnesses), and tumor risk on mortality in men with early-stage prostate cancer.
prostate cancer | Medivizor | source: Medivizor | Added Sep 09, 2021
Oncology Basics 2016
prostate cancer | Research | Treatment | 10 pages | source: The Lancet. Oncology | Added Sep 06, 2021
Evaluating the effectiveness and safety of talazoparib for the treatment of patients with metastatic castration-resistant prostate cancer.
This study evaluated the effectiveness and safety outcomes of talazoparib (Talzenna) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in DNA repair genes. The data showed that talazoparib was effective with manageable side effects for these patients.
prostate cancer | Research | 10 pages | source: JAMA network open | Added Sep 02, 2021
Evaluating the effects of various treatments on cognitive function in older men with resistant prostate cancer
This study aimed to investigate the link between various treatments for castration-resistant prostate cancer (CRPC) and cognitive (mental) dysfunction in older men. The main finding was that the treatments assessed did not appear to have an impact on cognitive function.